M. Komori

Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine, in healthy individuals

Takehiro Yamamoto, T. Sekida, Y. Kazami, 2023, medRxiv.

Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: A randomized, observer-blind phase 1 study

T. Fukuhara, Tomokazu Tamura, W. Akahata, 2023, Cell Reports Medicine.

saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern

M. R. Hassett, T. Fukuhara, Tomokazu Tamura, 2023, Nature communications.